HCC-UK comprises professionals of multidisciplines interested in improving outcomes for the increasing numbers of patients with hepatocellular carcinoma (HCC).
Date/Time: 30th March 2017
Venue: Vermont Hotel Newcastle (in Partnership with Hilton Gateshead)
HCC-UK 2017 will focus on:
- an update of surgical treatments for early stage disease
- locoregional and medical therapies for those with more advanced disease
- current best practice clinical management across early and more advanced stage disease
Case presentations, within a multidisciplinary environment, will play a key part of all sessions.
This meeting is accredited for 6 hours CPD and should appeal to all members of multidisciplinary teams, as well as trainees in gastroenterology and hepatology.
On behalf of HCC-UK, Helen Reeves would like to personally thank our sponsors for their generous and unconditional support. These include Bayer Healthcare, Boston Scientific, Bristol Myers Squibb, BTG, Gilead, Terumo and Sirtex
- HCC-UK 2017 - Agenda Programme (PDF: 146kB)
- HCC-UK 2017 - Speaker Biographies (PDF: 241kB)
- HCC-UK 2017 Flyer (PDF: 238kB)
Vermont Hotel Directions (PDF: 197kB)
HCC-UK is a multi-disciplinary group of professionals affiliated to BASL - The British Association for Study of the Liver.
HCC-UK is committed to:
- improving outcomes for the growing numbers of patients with HCC
- encouraging and facilitating collaborative nationwide research
- organising an annual meeting
- addressing the needs of the wider HCC community
- developing research strengths
HCC-UK current research initiatives include:
- performing retrospective and prospective national data collection for patients with HCC
- providing a national picture of diagnosis, stage, background liver disease, treatment allocation and outcomes
- evaluating novel strategies for HCC surveillance and stratification of treatment
Liver Cancer Research at Newcastle
The liver cancer research group carries out target discovery and validation on the molecular pathogenesis of HCC arising on a background of obesity, diabetes and non-alcoholic fatty liver disease (NAFLD). The group also investigates prognostic and predictive biomarkers for HCC and has created a liver cancer tissue bank with samples from over 500 patients with HCC.
The registration website has now closed. If you wish to attend HCC-UK 2017, please email Misti McCain